In conclusion, our modeling results indicated that the use of mpMRI after a positive PSA test followed by MRIGB can substantially reduce the risk of overdiagnosis and improve the harm-benefit ratio, while maximizing prostate cancer mortality reduction and QALYs gained, as compared to the regular screening pathway. The gene discussed is KLK3; the disease is prostate carcinoma.